Abstract
α-Synuclein (α-syn) is the main protein component of Lewy bodies, the major pathological hallmarks of Parkinson’s disease (PD). C-terminally truncated α-syn is found in the brain of PD patients, reduces cell viability and tends to form fibrils. Nevertheless, little is known about the mechanisms underlying the role of C-terminal truncation on the cytotoxicity and aggregation of α-syn. Here, we use nuclear magnetic resonance spectroscopy to show that the truncation alters α-syn conformation, resulting in an attractive interaction of the N-terminus with membranes and molecular chaperone, protein disulfide isomerase (PDI). The truncated protein is more toxic to mitochondria than full-length protein and diminishes the effect of PDI on α-syn fibrillation. Our findings reveal a modulatory role for the C-terminus in the cytotoxicity and aggregation of α-syn by interfering with the N-terminus binding to membranes and chaperone, and provide a molecular basis for the pathological role of C-terminal truncation in PD pathogenesis.
Subject terms: Nanoscale biophysics, Molecular neuroscience
C-terminal truncation of a-syn results in a more extended and exposed conformation, providing further insight into the pathological role of this truncation event in the progression of Parkinson’s disease.
Introduction
The soluble, disordered, monomeric protein, α-synuclein (α-syn) is abundant in presynaptic neurons and involved in neuronal function1. Insoluble aggregates of α-syn in Lewy bodies (LBs) are the hallmark of Parkinson’s disease (PD)2,3. α-Syn’s primary structure comprises three regions: the basic N-terminal domain (residues 1–60), which adopts an α-helix upon binding to negatively charged membranes4–6; the hydrophobic NAC domain (residues 61-95), which is prone to aggregation and form fibrils7–9; and the flexible C-terminal domain (residues 96–140), which contains many negatively charged residues and interacts with cations and polyamines10,11.
Multiple forms of C-terminally truncated α-syn (CT-α-syn) are detected in normal and PD brains12–16, and widely investigated due to their remarkable ability to aggregate and transform into pathologic fibrils. CT-α-syn accelerates formation of oligomers and fibrils compared to the full-length protein (FL-α-syn) in vitro17–27. When co-expressed with FL-α-syn, CT-α-syn promotes the pathological accumulation of FL-α-syn28,29. Deleting C-terminal residues accelerates aggregation up to residues 85-90, where the NAC domain begins. Further truncation decreases aggregation propensity because the NAC region forms the core of amyloid fibrils7,18,30. Cells expressing CT-α-syn are more vulnerable to oxidative stress and CT-α-syn is more toxic than FL-α-syn21,31–33. Transgenic mice expressing C-terminal truncated species manifest PD-like symptoms34. These observations suggest a role for CT-α-syn in PD, but the causes are largely unknown.
Based on this variety of cytotoxicity, plenty of attention has been paid to the role of the C-terminus in α-syn pathology, such as C-terminal-engaged interactions and the effect of the C-terminus on fibrillation. The native compact conformation of monomeric α-syn is driven by the long-range transient intramolecular interactions between the N- and C-termini, release of which accelerates aggregation35,36. α-Syn’s N-terminus is responsible for the fibril core, but also interacts with membranes and chaperones, which modulates fibrillation37,38. For instance, the N-terminal domain regulates fusion of synaptic vesicles and subsequent neurotransmitter release, which are critical for normal brain function39,40. Molecular chaperones, such as protein disulfide isomerase (PDI) and Hsp70, bind to the N-terminal domain, dissolve and degrade accumulated misfolded α-syn, highlighting the role of chaperones in preventing α-syn aggregation and regulating its physiological function41–43. Yet it is unknown whether long-range intramolecular interactions between the N- and C-terminus affect the association of the N-terminus with other molecules and the implications in pathological toxicity. Does C-terminal truncation free the N-terminal domain to interact with membranes and chaperones, thus affecting α-syn functionality?
Here, we investigate the effects of C-terminal truncation on the interactions of the N-terminus with membranes and molecular chaperones using FL- and CT-α-syn (residues 1-99). Nuclear magnetic resonance spectroscopy (NMR) and coflotation data reveal a stronger interaction of CT-α-syn with membranes and with PDI, a major endoplasmic reticulum chaperone44. The interaction may arise from a more extended conformation of CT-α-syn, as opposed to the compact conformation of FL-α-syn45. The functional assay reveals severe mitochondrial membrane disruption by CT-α-syn compared to FL-α-syn in both neuronal cells and isolated mitochondria. Dramatically differential inhibitory effects of PDI on FL-α-syn and CT-α-syn fibrillation are also observed. Our results suggest that the C-terminus behaves like a ‘guard’ regulating α-syn function. In addition to homogeneous intermolecular interplays associated with self-assembly, it affects N-terminal interactions with other molecules. The absence of this ‘guard’ exposes the N-terminus, resulting in stronger interaction with membranes and chaperone, mitochondrial dysfunction and diminishes the inhibitory effect of chaperone, all of which could affect the etiology of PD.
Results
C-terminal truncation causes stronger interactions with membranes and PDI
Under physiological conditions, about 15% of α-syn exists as membrane-bound form46. Several studies highlight a specific interaction of α-syn with the acid phospholipid cardiolipin (CL), a lipid unique to mitochondria, which is postulated to be associated with PD47–50. α-Syn forms a N-terminal α-helix upon binding to negatively charged membranes, without involvement of the C-terminus4, but it is not known if deleting the C-terminus affects binding. We thus prepared mixtures comprising palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/CL (7:3 mole ratio) to mimic mitochondrial membranes and POPC/1-palmitoly-2-oleoyl-sn-glycero-3-phosphate (POPA) (1:1 mole ratio) lipid mixture to obtain highly anionic liposomes. Binding of FL- and CT-α-syn (residues1-99) was analyzed by coflotation, a common method for studying protein-lipid interaction. Liposomes, and liposomes-associated proteins float to the top of the gradient and unbound proteins to the bottom (Fig. 1b). The fractions from top to bottom were collected and quantified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Fig. 1c and Supplementary Fig. 1a). For both synthetic mitochondrial membranes and 50% POPA anionic membranes, ~80% of the CT-α-syn and 50–60% of FL-α-syn binds (Fig. 1d, Supplementary Fig. 1b and Supplementary Data 1), indicating stronger association of CT-α-syn. Considering packing defects possibly promoting the interaction between CT-α-syn and membrane due to the small headgroup of POPA and CL, we employed 30% POPS (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-l-serine), a similar anionic lipid but with a larger headgroup. Similarly, the population of membrane-bound CT-α-syn is larger than that of membrane-bound FL-α-syn (50% versus 25%, Supplementary Fig. 1a, b), suggesting that CT-α-syn interacts more strongly with membranes.
To further confirm our findings, we acquired 1H-15N heteronuclear single quantum coherence (HSQC) spectra of uniformly 15N-enriched FL- and CT-α-syn in the presence of POPC/CL (7:3 mole ratio) liposomes, POPC/POPA (1:1 mole ratio) liposomes, POPC/POPS (7:3 mole ratio) liposomes, respectively. NMR provides binding information at the residue level because resonances from strongly bound residues show reduced intensities51. Analysis of spectra acquired in the absence and presence of liposomes (Fig. 1e and Supplementary Fig. 1c, d) indicate that, consistent with previous results, the N-terminus dominates binding5. Data for CT-α-syn show that signals are more attenuated in the presence of liposomes containing CL, POPA or POPS compared to FL-α-syn, indicating a stronger binding of CT-α-syn to membranes than FL-α-syn, consistent with the coflotation data.
Molecular chaperones are another important binding partner of the N-terminal region of α-syn in mammalian cells38. PDI interacts with the hydrophobic region of the N-terminal region, inhibiting aggregation43,52,53. To investigate the impact of the C-terminal truncation on the interaction with PDI, we acquired 1H-15N HSQC spectra of uniformly 15N-enriched FL- and CT-α-syn in the presence of PDI at a mole ratio of 2:1, which enabled us to assess intermolecular interactions at the residue level via chemical shift perturbations (CSPs) and intensity changes. PDI binds the first 20 residues of FL-α-syn (segment 1) and 10 residues near Tyr39 (segment 2) (Fig. 2a, b). Both sites are located at the N-terminus, consistent with other reports38,43. Although the attenuation patterns of CT- and FL-α-syn in PDI are similar, there are differences in chemical shift and intensity (Fig. 2c), suggesting the constructs have similar PDI-binding sites but different affinities. As most signals of α-syn in segment 1 and 2 disappear when the mole ratio of PDI to α-syn is greater than 1:1, we quantied the dissociation constants (KD) of FL- and CT-α-syn by fitting the average CSPs values of residues within segment 1 and segment 2 as a function of the concentration of PDI (Fig. 2d and Supplementary Data 2) up to 0.3 mM. CSP values of FL- and CT-α-syn at 0.6 mM PDI were predicted by fitting the curve. The fitting results show that segment 2 of FL- and CT-α-syn have similar KD values (~400 μM), whereas segment 1 of CT-α-syn has a KD of ~40 μM, which is much smaller than that of FL-α-syn (~700 μM).
C-terminal truncated α-syn exhibits a more extended conformation
Given the difference in membrane binding between FL- and CT-α-syn, we examined the constructs using paramagnetic relaxation enhancement (PRE) to determine whether deleting the C-terminus alters the ensemble of conformations. We prepared spin-labeled proteins by incorporating 1-oxyl-2,2,5,5-tetramethyl-delta3-pyrroline-3-methyl (MTSL), a paramagnetic spin label, into single cysteine variants (A90C) of 15N-enriched FL- and CT-α-syn. Cross-peaks arising from residues close to the label broaden due to enhanced transverse relaxation. As reported35, intramolecular interactions between the N- and C-terminal regions lead to broadening proximal to the spin label and in residues within the N-terminal region, neighboring Tyr39 (Fig. 3a), while the N-terminal residues of CT-α-syn show weak PRE effects (Fig. 3b). These results indicate that the interactions between the N- and C-terminal regions cause the PRE effects observed in FL-α-syn, and similar intramolecular long-range interactions are absent in CT-α-syn. We conclude that CT-α-syn exhibits a more extended conformation.
Effects of C-terminus truncation on physiological and pathological functions
α-Syn localizes to mitochondria in the human brain, and the association of α-syn with the mitochondrial membrane is related to mitochondrial dysfunction54–56. To better understand the membrane-related physiological differences between FL- and CT-α-syn, we evaluated the mitochondrial potential in living SK-N-SH cells using the dye, 5, 5′, 6, 6′-tetrachloro-1, 1′, 3, 3′-tetraethylbenzimidazolocarbocyanine iodide (JC-1). In normal cells, JC-1 aggregates in the matrix due to the electrochemical potential gradient resulting in the red fluorescence. Apoptotic events cause monomeric JC-1 to disperse throughout the cell resulting in green fluorescence. Images of SK-N-SH cells were acquired after treatment with 50 μM FL- or CT-α-syn for 5 h. Mitochondria in untreated SK-N-SH cells stain bright red, but red fluorescence decreased markedly in CT-α-syn-incubated cells concomitant with an increase in green fluorescence, indicating collapse of the mitochondrial membrane potential (Fig. 4a). The green/red fluorescence intensity ratio showed no significant difference between FL-α-syn-treated and control cells (Fig. 4b and Supplementary Data 3). Thus, the C-terminal truncation increases mitochondrial damage compared to the negative control and FL-α-syn. We excluded the possibility that CT-α-syn aggregated into oligomers or fibrils during 5 h incubation with SK-N-SH cells (Supplementary Fig. 2), thus the cytotoxicity of CT-α-syn may be mainly caused by enhanced monomer-membrane interactions.
To further confirm the functional consequences of CT-α-syn on mitochondria, we isolated mitochondria from SK-N-SH cells. Given the dissipated membrane potential, we anticipated mitochondrial membrane permeabilization, allowing cytochrome c (cyto c) release57,58. We assessed release of cyto c after treatment of mitochondria with various concentrations of FL- and CT-α-syn for 1 h at 37 °C (Fig. 4c) via Western blotting. Enhanced release relative to control mitochondria was detected with CT-α-syn. We did not observe a significant release of cyto c compared to controls with FL-α-syn. This result lends support to the idea that CT-α-syn disrupts mitochondrial membrane, leading to cyto c release.
To understand the influence of C-terminal truncation on membrane interactions, we used dynamic light scattering to monitor the formation of POPC/CL liposome clusters in the presence of FL- and CT-α-syn. FL-α-syn barely clusters liposomes while CT-α-syn dramatically increases particle size (Fig. 4d). The results agree with our NMR data showing that CT-α-syn interacts more strongly with liposomes than FL-α-syn. Hence, the ability of CT-α-syn to cluster liposomes arises from a stronger membrane interaction, which could disrupt membranes.
To investigate the effect of chaperone binding on CT-α-syn aggregation, we used Thioflavin T (ThT) fluorescence to monitor the rate of CT-α-syn aggregation in the absence or presence of an equal molar ratio of PDI and compared the rate to that of FL-α-syn. The ß-sheet structure of amyloid fibrils binds ThT dye enhancing fluorescence59. Figure 4e shows a typical nucleation-aggregation profile, beginning with a lag phase, followed by an elongation phase, and ending in a plateau. In the absence of PDI, truncation of the C-terminus accelerates CT-α-syn aggregation with a decreased lag time compared to FL-α-syn (Table 1, Fig. 4e and Supplementary Data 3). This result points to an auto-inhibitory role for the C-terminus on fibrillation, consistent with the previous studies20,23,60. As expected, the presence of PDI inhibits FL-α-syn aggregation52,61,62, but inhibits CT-α-syn aggregation to a somewhat smaller extent, as reflected by an over 3-fold increase in lag time for FL-α-syn whereas less than 2-fold for CT-α-syn. Besides, half-time of aggregation (t1/2) clearly shows that PDI exerted a less inhibitory effect on CT-α-syn aggregation (Fig. 4f and Supplementary Data 3), though segment 1 of CT-α-syn interacting more strongly with PDI.
Table 1.
Protein | tlag (h)a | k b | t1/2 (h)c |
---|---|---|---|
FL-α-syn | 7.4 ± 0.4 | 0.65 ± 0.03 | 10.5 ± 0.3 |
CT-α-syn | 2.1 ± 0.3 | 1.1 ± 0.1 | 4.0 ± 0.3 |
Y39E-α-syn | NDd | NDd | NDd |
FL-α-syn +PDI | 23 ± 2 | 0.28 ± 0.05 | 30 ± 3 |
CT-α-syn +PDI | 4.0 ± 0.3 | 0.7 ± 0.1 | 6.9 ± 0.6 |
Y39E-α-syn+PDI | 36 ± 2 | 0.21 ± 0.03 | 46 ± 1 |
aLag time.
bElongation rate constant.
cHalf-time of aggregation.
dPlateau was not reached.
Segment 2, comprising residues 36–42, is reported to be the ‘master controller’ of α-syn aggregation at neutral pH63. We hypothesized that the stronger interaction of PDI with segment 1 of CT-α-syn explains the diminished inhibitory effect on aggregation. To test this idea, we changed Tyr39 to Glu (Y39E) in segment 2 to weaken its affinity for PDI. As expected, the mutation abolishes the interaction of segment 2 with PDI whereas segment 1 still bound tightly (Supplementary Fig. 3a–c). While t1/2 of the variant in the absence of PDI was too long to measure, the ThT fluorescence assay indicates an increased aggregation rate in the presence of PDI, with t1/2 of about 45 h (Table 1, Supplementary Fig. 3d, e), suggesting that segment 2 is a controller and segment 1 acts as an accelerator of fibrillation upon binding to PDI. These results indicate that the interaction of PDI with segment 1 is enhanced in CT-α-syn, resulting in a diminished inhibition effect of PDI on fibrillation.
Discussion
Misfolded, oligomeric, and fibrillar α-syn contribute to neuronal toxicity and progression of PD64–66. The proposed transient long-range interaction between the N-terminus and acidic tail of α-syn may inhibit fibril formation67. Releasing these contacts destabilizes the natively unfolded monomers potentiating aggregation35,68. For instance, Ca2+, Cu2+ and polyamine binding alters α-syn’s long-range interaction exposing the amyloidogenic NAC region, resulting in enhanced fibrillation60. Here, we observe a conformational change for C-terminally truncated α-syn. The results suggest that deleting the C-terminus disrupts the intramolecular long-range interaction between the N- and C-terminus such that CT-α-syn adopts a relatively extended conformation in which the N-terminus is more exposed (Fig. 3b), suggesting an auto-chaperoning role of the C-terminus by shielding the N-terminus of α-syn, in agreement with previous reports20,69–72.
Our finding that truncating the C-terminal region facilitates membrane binding contradicts a report purporting to show that the deletion has no effect73. However, our NMR data (Fig. 1e and Supplementary Fig. 1c, d) show attenuated signals of CT-α-syn in the presence of liposomes compared to FL-α-syn, supporting our coflotation data (Fig. 1c, d and Supplementary Fig. 1a, b) indicating more membrane-bound CT-α-syn compared to FL-α-syn. The dynamic light scattering data (Fig. 4d) also demonstrate stronger interaction of CT-α-syn with membrane. α-Syn binds membranes via electrostatic interactions involving the positively charged N-terminus with the negatively charged acid headgroups of phospholipid, and hydrophobic interactions between hydrophobic residues and fatty acyl chain of the phospholipid74. Hence, exposing the N-terminus strengthens the binding to liposomes.
α-Syn directly associates with mitochondrial membrane, and membrane interaction is a common cause of membrane disruption by the intrinsically disordered proteins48,75. After establishing the stronger interaction of CT-α-syn with artificial mitochondrial membranes, we turned to the physiological effect on mitochondrial membrane potential in living SK-N-SH cells. Using JC-1 staining, the data (Fig. 4a, b) show CT-α-syn collapses the potential, which coincides with cyto c release (Fig. 4c). By contrast, FL-α-syn does not impact cyto c release or membrane potential. α-Syn causes mitochondrial fragmentation via direct interaction with mitochondrial membranes, and these fragmented mitochondria are present in neurons and LBs along with α-syn deposits, including truncated forms76–79. The stronger interaction of CT-α-syn with mitochondrial membranes sheds light on the basis of toxicity and mitochondrial dysfunction induced by CT-α-syn.
Molecular chaperones help dissolve α-syn aggregates and prevent formation of pathological fibrils. For instance, Hsp70, a mammalian chaperone, breaks α-syn fibrils into monomers or oligomers41,42. The common chaperone binding region of α-syn is in the N-terminus. Our data showing that PDI binds two segments in the N-terminus (Fig. 2a–c) are consistent with the result of Yagi-Utsumi et al.43 In addition, we find that segment 1 in CT-α-syn binds more tightly to PDI, compared to FL-α-syn, while segment 2 has a similar affinity (Fig. 2d). Using in vitro fibrillation assay, we find that the stronger interaction of segment 1 diminishes the inhibitory effect of PDI on CT-α-syn aggregation (Table 1, Fig. 4e, f). Upon decreasing the affinity of segment 2 for PDI and retaining the segment 1 by mutating Tyr39 to Glu (Y39E, Supplementary Fig. 3a–c), we observed faster aggregation in the presence than in the absence of PDI (Table 1, Supplementary Fig. 3d, e), further supporting the role of segment 1 as an accelerator of fibrillation when binding to PDI. Our results reinforce the importance of residues near Tyr39 in manipulating aggregation, reveal the differential effect of segment 1 and 2 on the fibrillation upon binding to PDI, and may provide a clue for chaperone-based design of fibrillation inhibitors. Nevertheless, the C-terminal truncation frees the N-terminus also enhancing the association with molecular chaperone, which is eventually reflected in the weakened inhibitory effect on CT-α-syn fibrillation.
Our results, along with those others35,36, demonstrate the presence of the long-range interactions between the N- and C-terminal regions which are disrupted by the C-terminal truncation leaving the N-terminus largely exposed. In this work, we find that the C-terminal region of α-syn balances the interactions of the N-terminus with the membranes and chaperones. In view of this, we propose a mechanism for how CT-α-syn might be involved in PD pathogenesis(Fig. 5). The long-range interactions between the N- and C-terminal regions keep α-syn in its compact conformation, while the more extended conformation of CT-α-syn favors the heterogeneous intermolecular interactions of α-syn, such as with membrane and chaperone. Chaperones help cells handle misfolded proteins but when the C-terminus is truncated, segment 1 in the exposed N-terminus has an enhanced interaction with PDI resulting in partly uncontrolled fibrillation. Moreover, the stronger interaction between the CT-α-syn and mitochondrial membrane collapses the mitochondrial membrane potential and enhances membrane permeability, causing cyto c release. Based on previous studies and our results, we proposed that the mitochondrial dysfunction likely activates the apoptosome and the NLRP3 inflammasome80–85, which may lead to more truncation of FL-α-syn, forming a negative-feedback loop that amplifies truncation and elicits cell death86–88. Our observations highlight the guard role of the C-terminus in the cytotoxicity and aggregation of α-syn and show the importance of maintaining intact α-syn in cells. We propose that reducing C-terminal truncation is a plausible way to prevent the onset or development of PD.
The C-terminal truncation releases the long-range interactions between the N- and C-terminal domains of α-syn. CT-α-syn exhibits a more extended conformation, resulting in stronger interactions with membranes and molecular chaperones. The truncation further causes mitochondrial damage and accelerates fibrillation, both are key aspects of pathogenesis. We conclude that the C-terminus plays an auto-inhibitory role in FL-α-syn, shielding the N-terminus from heterogeneous intermolecular interactions, and acting as a ‘guard’, fending off cytotoxicity and aggregation of α-syn by maintaining moderate α-syn-membrane interactions and inhibitory effect of chaperones on fibrillation. We speculate that preventing truncation is a strategy for preventing the onset or development of PD and synucleinopathies26,27,33,89.
Methods
Protein expression and purification
α-Syn mutants containing a deletion of the C-terminus (amino acids 1-99), single cysteine mutants and single glutamic acid mutant were generated by using site-directed mutagenesis. Natural abundance and 15N-enriched α-syn and its variants were expressed in Escherichia coli BL21 (DE3) cells in either LB media or M9 minimal medium supplemented with 15NH4Cl. The cells were grown at 37 °C to an optical density at 600 nm (OD600) of 0.6 and induced with 1 mM IPTG for 4 h. Cells were harvested by centrifugation at 6300 g for 10 min at 4 °C. FL-α-syn was purified as described90. Cells expressing FL-α-syn or FL-A90C were homogenized by a high-pressure homogenizer (ATS Engineering) prior to boiling the cell lysates for 20 min, making most cellular proteins precipitated. Then streptomycin sulfate (10 mg/mL) was added to supernatant and was rotated at 4 °C for 30 min followed by the centrifugation at 14,000g for 30 min at 4 °C, this procedure was repeated again by adding ammonium sulfate (360 mg/mL) to supernatant. The final pellet was resuspended in 20 mM Tris, pH 7.6 and loaded onto a DEAE column, finally eluted in a gradient of 0-1000 mM NaCl. Protein purity was analyzed by SDS-PAGE. For CT-α-syn and CT-A90C, cells were resuspended in 1 mM PMSF, 50 mM MES, pH 6.0 and lysed. Cell lysates were centrifuged at 48,000g for 30 min at 4 °C. The supernatant was introduced into a SP cation exchange column (GE Healthcare) and the column eluted in a gradient of 0-1000 mM NaCl. Fractions containing the proteins were concentrated after SDS-PAGE analysis and then chromatographed on a Superdex 75 26/600 column (GE Healthcare) eluted with 50 mM MES and 200 mM NaCl, pH 6.0.
The human PDI gene was cloned into a pET-28a vector containing a His6-tag and a TEV protease cleavage site at the N terminus. The recombinant vector was transformed into E. coli BL21 (DE3). The cells were cultured in LB medium at 37 °C. When cell density reached an OD600 of 0.8, PDI expression was induced with 1 mM IPTG for 7 h. Cells harvested by centrifugation were resuspended in 20 mM Tris, 500 mM NaCl, pH 8.0 with freshly prepared 10 mg/L protease inhibitors (Sigma-Aldrich). After lysis and centrifugation, the soluble fraction applied to a HisTrap column (GE Healthcare), which was eluted with a linear gradient of 0–500 mM imidazole. Protein was further purified by anion exchange chromatography with a Resource Q column (GE Healthcare) using 20 mM Tris, pH 8.0 and eluted by a linear gradient of 0-1000 mM NaCl, followed by size-exclusion chromatography with a Superdex 200 16/600 column (GE Healthcare) equilibrated with 20 mM Tris, 300 mM NaCl, pH 8.0. Protein concentration was determined either by absorbance of aromatic amino acids at 280 nm with a NanoDrop spectrophotometer (extinction coefficients is 45.38, 5.96 and 1.49 for PDI, FL- and CT-α-syn, respectively), or by Bradford assay using BSA as a standard. Purified proteins were desalted using a HiTrap column (GE Healthcare), lyophilized and stored at −80 °C.
Liposome preparation
POPC, POPA, POPS and CL were purchased from Avanti Polar Lipids (Alabaster, AL) and used without purification. Liposomes containing 50% POPC and 50% POPA, and liposomes containing 70% POPC and 30% CL were prepared as described91,92. Briefly, lipid powders were mixed and dissolved in CHCl3. Solution of lipid mixtures were dried, and lipids were hydrated with liposome buffer (20 mM HEPES, 100 mM KCl, pH7.0) to a final concentration of 24 mM. After that, the lipids were sonicated for 10 min with 30% output to prepare liposomes.
Liposome coflotation assay
The assay was performed as described93,94. Briefly, 20 μM FL- and CT-α-syn were individually incubated with 6 mM liposomes in a total volume of 375 μL liposome buffer (20 mM HEPES, 100 mM KCl, pH7.0) for 30 min at room temperature. After incubation, 375 μL iohexol [80% (w/v)] in liposomes buffer was added to protein-liposomes mixture (40% final density). In a thick-wall centrifugation tube (Beckman), 300 μL of liposome buffer was on top with 375 μL of 30% iohexol and 375 μL of 35% iohexol underneath, 750 μL of 40% iohexol was placed at the bottom. A SW60Ti rotor (Beckman) was used for gradient centrifugation at 280,000 g for 150 min at 4 °C to separate lipid-bound and unbound proteins. After that, liposomes and liposomes-associated proteins floated to the top of the gradient. The mixture was then deconstructed from the top to the bottom into nine equal fractions. Each fraction was mixed with 5 × SDS loading buffer, and 10 μL was subjected to SDS-PAGE. To better resolve FL- or CT-α-syn bands, lipids were allowed to migrate out of the gel as much as possible. Image J software (National Institutes of Health) was used to quantify band intensity.
1H-15N Heteronuclear single quantum coherence
Spectra from membrane-binding experiments were acquired using 0.1 mM 15N-enriched FL- and CT-α-syn dissolved in NMR buffer (20 mM HEPES, 100 mM KCl, pH7.0) plus 10% (v/v) D2O in the absence or presence of 12 mM liposomes. 1H-15N HSQC spectra from PDI-binding experiments were acquired using 0.3 mM 15N-enriched FL- and CT-α-syn dissolved in 20 mM HEPES, 100 mM NaCl, 5 mM tris (2-carboxyethyl) phosphine, pH 7.0, 10% (v/v) D2O in the absence, or presence of PDI at mole ratios from 10:1 to 1:1. Experiments were carried out at 15 °C on a Bruker Avance 800 or 850 MHz NMR spectrometer. Resonance assignments for α-syn are available from the BioMagResBank (entry number 16543). Data were analyzed with Sparky software. Intensity ratios were calculated by peak heights in the presence and absence of liposomes or PDI. CSPs of backbone amides were calculated according to Eq. (1)95, where ΔδH and ΔδN denote the chemical shift difference in the absence and presence of PDI in the 1H and 15N dimension, respectively.
1 |
KD was calculated using the fitting function shown in Eq. (2)96:
2 |
where Δδobs is the observed FL- or CT-α-syn chemical shift minus the free FL- or CT-α-syn shifts, [P]t represents the concentration of FL- or CT-α-syn (300 μM), and [L]t represents PDI concentration, from 0 to 300 μM.
Paramagnetic relaxation enhancement
For spin label (MTSL) conjugation, single cysteine variants of 15N-enriched FL- and CT-α-syn (FL- and CT-A90C) were dissolved in NMR buffer and reduced with 5 mM DTT for 30 min. The proteins were then reacted with a 5-fold mole excess of MTSL at 4 °C for 16 h in the dark. Excess MTSL was removed by eluting samples over a HiTrap desalting column (GE Healthcare) into NMR buffer. Complete labeling was confirmed by LC-MS. Spin-labeled FL- and CT-α-syn were lyophilized or used directly. Intramolecular PRE experiments required 100 μM 15N-MTSL-labeled protein. PRE experiments were conducted in NMR buffer containing 10% (v/v) D2O at 15 °C using a Bruker Avance 850-MHz spectrometer. Diamagnetic samples were prepared by adding a 10-fold mole excess of ascorbic acid to the paramagnetic samples. PRE data were processed using NMRpipe-software and analyzed with Sparky- software. PRE effects were quantified as the ratios of peak intensities recorded in the paramagnetic state versus the diamagnetic state, respectively. The transverse relaxation rate enhancements (R2) could be calculated with Eq. (3)97:
3 |
where Idia, Ipara denote NMR signal intensity in the diamagnetic and paramagnetic state, respectively, the interval time Tb−Ta, was 17.2 ms for FL-α-syn and 20 ms for CT-α-syn.
Mitochondrial membrane potential
SK-N-SH cells (purchased from Procell, CL-0214) were incubated with 50 μM FL- and CT-α-syn in growth medium at 37 °C for 5 h. The JC-1 kit (Sigma-Aldrich) provided the prepared reagents and was used according to manual. Images were acquired with a confocal fluorescence microscope (Leica TCS SP8). Fluorescence intensity was analyzed with Image J software.
Cytochrome c release
SK-N-SH cells were cultured in MEM supplemented with 10% fetal bovine serum and antibiotics in a humidified atmosphere of 5% CO2 at 37 °C. At least 107 SK-N-SH cells were used per experiment. The mitochondria were prepared with a Mitochondria Isolation Kit (Solarbio) for cultured cells. Freshly isolated mitochondria were resuspended in ice cold buffer (10 mM HEPES, 2 mM K2HPO4, 10 mM succinate, 250 mM sucrose, 1 mM ATP, 0.08 mM ADP, 1 mM DTT, pH 7.5)56. Aliquots were incubated with FL- or CT-α-syn at 37 °C for 1 h. After incubation, the mixture was centrifuged at 13000 g at 4 °C for 10 min. An equal volume of the supernatant was subjected to SDS-PAGE and the band transferred to a nitrocellulose membrane. The membrane was blocked in TBS-T (20 mM Tris, 150 mM NaCl, 0.05% Tween-20, pH 8.0) with 5% skim milk overnight at 4 °C prior to the adding anti-cyto c monoclonal antibody (Abcam, Cat.ab133504, 1:1000 dilution) and incubating for 1 h at room temperature. Following three washes with TBS-T, the membrane was incubated with goat anti-rabbit-HRP secondary antibody in blocking buffer (Beijing Biodragon, Cat.BF03008, 1:5000 dilution) in TBS-T with 5% skim milk for 1 h at room temperature. The membrane was visualized by enhanced chemiluminescence reagents (BioRad) after another three washes.
Dynamic light scattering
FL- or CT-α-syn (20 μM) were incubated with 100 μM liposomes in a total volume of 1 ml of NMR buffer at room temperature for 30 min. Clustering activity was measured by dynamic light scattering using a Protein Solutions DynaPro instrument (Malvern) in triplicate, with an average of 10 data points. Particle size distribution of liposomes for control experiments was monitored under same conditions.
Fibrillation monitored by thioflavin T fluorescence
FL- or CT-α-syn (0.3 mM) was mixed with or without 0.3 mM PDI in 20 mM Tris, 100 mM NaCl, 2 mM tris (2-carboxyethyl) phosphine, pH 7.5, 0.01% (w/v) NaN3 and filtered through a 0.22 μm Millex filter. Samples (200 μL) containing 15 μM ThT were dispensed along with a 2.5-mm glass bead in each well of a black, transparent bottomed, 96-well plate. The plate was sealed with a Al sealing tape (Corning) and incubated in a SpectroMax i3x microplate reader (Molecular Devices) at 37 °C with 500 rpm high-grade orbital shaking. ThT fluorescence was measured every 10 min using excitation and emission wavelengths of 444 nm and 482 nm, respectively. The data were analyzed using Eq. (4)10:
4 |
F(t) was normalized by dividing the largest value in each experiment, k represents the fibrillation rate constant and t1/2 is the aggregation half-time. The lag time tlag was calculated as .
Statistics and reproducibility
Data were expressed as mean ± SEM from three to four independent experiments. Bar graphs were shown in dot-plot format showing data distribution. Statistics were analyzed by one-way ANOVA and *p < 0.05, **p < 0.01 and ***p < 0.001 were considered as significant differences. The number of replicates were described in the figure legends.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Supplementary information
Acknowledgements
This work is supported by the National Key R&D Program of China (2018YFE0202300), the National Natural Sciences Foundation of China (21673284, 21925406 and 21991080) and K. C. Wong Education Foundation.
Author contributions
C.Z., Y.P., Z.Z. L.J., G.J.P., X.Z., M.L., and C.L. conceived the study. C.Z., Y.P., Z.Z., L.X., and X.L. performed the experiments. C.Z., Y.P., Z.Z., L.J., G.J.P., X.Z., M.L., and C.L. analyzed the data. C.Z., Z.Z., L.J., G.J.P., X.Z., M.L., and C.L. wrote the manuscript.
Peer review
Peer review information
Communications Biology thanks Aditya Iyer and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors: Krishnananda Chattopadhyay and George Inglis.
Data availability
The full and uncropped gel/blot images are shown in Supplementary Fig. 4. All data generated or analyzed during this study are included in the article and Supplementary Data 1–3.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Cai Zhang, Yunshan Pei.
Contributor Information
Zeting Zhang, Email: zhangzeting@apm.ac.cn.
Conggang Li, Email: conggangli@apm.ac.cn.
Supplementary information
The online version contains supplementary material available at 10.1038/s42003-022-03768-0.
References
- 1.Benskey MJ, Perez RG, Manfredsson FP. The contribution of alpha synuclein to neuronal survival and function - implications for Parkinson’s disease. J. Neurochem. 2016;137:331–359. doi: 10.1111/jnc.13570. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840. doi: 10.1038/42166. [DOI] [PubMed] [Google Scholar]
- 3.Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA. 1998;95:6469–6473. doi: 10.1073/pnas.95.11.6469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998;273:9443–9449. doi: 10.1074/jbc.273.16.9443. [DOI] [PubMed] [Google Scholar]
- 5.Bartels T, et al. The N-terminus of the intrinsically disordered protein α-synuclein triggers membrane binding and helix folding. Biophys. J. 2010;99:2116–2124. doi: 10.1016/j.bpj.2010.06.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Eliezer D, Kutluay E, Bussell R, Jr., Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 2001;307:1061–1073. doi: 10.1006/jmbi.2001.4538. [DOI] [PubMed] [Google Scholar]
- 7.Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 2001;276:2380–2386. doi: 10.1074/jbc.M008919200. [DOI] [PubMed] [Google Scholar]
- 8.Rodriguez JA, et al. Structure of the toxic core of α-synuclein from invisible crystals. Nature. 2015;525:486–490. doi: 10.1038/nature15368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Cho MK, et al. Structural characterization of alpha-synuclein in an aggregation prone state. Protein Sci. 2009;18:1840–1846. doi: 10.1002/pro.194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Fernandez CO, et al. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J. 2004;23:2039–2046. doi: 10.1038/sj.emboj.7600211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Eliezer D. The mysterious C-terminal tail of alpha-synuclein: Nanobody’s guess. J. Mol. Biol. 2013;425:2393–2396. doi: 10.1016/j.jmb.2013.03.031. [DOI] [PubMed] [Google Scholar]
- 12.Anderson JP, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006;281:29739–29752. doi: 10.1074/jbc.M600933200. [DOI] [PubMed] [Google Scholar]
- 13.Muntane G, Ferrer I, Martinez-Vicente M. α-Synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience. 2012;200:106–119. doi: 10.1016/j.neuroscience.2011.10.042. [DOI] [PubMed] [Google Scholar]
- 14.Bhattacharjee P, et al. Mass spectrometric analysis of Lewy body-enriched α-Synuclein in Parkinson’s disease. J. Proteome Res. 2019;18:2109–2120. doi: 10.1021/acs.jproteome.8b00982. [DOI] [PubMed] [Google Scholar]
- 15.Delcourt V, et al. Spatially-resolved top-down proteomics bridged to MALDI MS imaging reveals the molecular physiome of brain regions. Mol. Cell. Proteom. 2018;17:357–372. doi: 10.1074/mcp.M116.065755. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Li W, et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson’s disease-linked mutations. Proc. Natl Acad. Sci. USA. 2005;102:2162–2167. doi: 10.1073/pnas.0406976102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Sorrentino ZA, et al. Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions. J. Biol. Chem. 2018;293:18914–18932. doi: 10.1074/jbc.RA118.005603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Murray IV, et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry. 2003;42:8530–8540. doi: 10.1021/bi027363r. [DOI] [PubMed] [Google Scholar]
- 19.Iyer A, et al. C-terminal truncated α-Synuclein fibrils contain strongly twisted β-sheets. J. Am. Chem. Soc. 2017;139:15392–15400. doi: 10.1021/jacs.7b07403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Levitan K, et al. Conserved C-terminal charge exerts a profound influence on the aggregation rate of α-synuclein. J. Mol. Biol. 2011;411:329–333. doi: 10.1016/j.jmb.2011.05.046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Ma L, et al. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson’s disease. Biochim. Biophys. Acta, Mol. Basis Dis. 2018;1864:3714–3725. doi: 10.1016/j.bbadis.2018.10.003. [DOI] [PubMed] [Google Scholar]
- 22.Ni X, McGlinchey RP, Jiang J, Lee JC. Structural insights into α-synuclein fibril polymorphism: effects of Parkinson’s disease-related C-terminal truncations. J. Mol. Biol. 2019;431:3913–3919. doi: 10.1016/j.jmb.2019.07.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.van der Wateren IM, Knowles TPJ, Buell AK, Dobson CM, Galvagnion C. C-terminal truncation of α-synuclein promotes amyloid fibril amplification at physiological pH. Chem. Sci. 2018;9:5506–5516. doi: 10.1039/C8SC01109E. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Sorrentino ZA, Xia Y, Gorion KM, Hass E, Giasson BI. Carboxy-terminal truncations of mouse α-synuclein alter aggregation and prion-like seeding. FEBS Lett. 2020;594:1271–1283. doi: 10.1002/1873-3468.13728. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.McGlinchey RP, et al. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson’s disease. J. Biol. Chem. 2019;294:9973–9984. doi: 10.1074/jbc.RA119.008930. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Terada M, et al. The effect of truncation on prion-like properties of α-synuclein. J. Biol. Chem. 2018;293:13910–13920. doi: 10.1074/jbc.RA118.001862. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Games D, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J. Neurosci. 2014;34:9441–9454. doi: 10.1523/JNEUROSCI.5314-13.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur. J. Neurosci. 2010;32:409–422. doi: 10.1111/j.1460-9568.2010.07284.x. [DOI] [PubMed] [Google Scholar]
- 29.Volpicelli-Daley LA, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57–71. doi: 10.1016/j.neuron.2011.08.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Stephens AD, et al. Extent of N-terminus exposure of monomeric alpha-synuclein determines its aggregation propensity. Nat. Commun. 2020;11:2820. doi: 10.1038/s41467-020-16564-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Stefanova N, Klimaschewski L, Poewe W, Wenning GK, Reindl M. Glial cell death induced by overexpression of alpha-synuclein. J. Neurosci. Res. 2001;65:432–438. doi: 10.1002/jnr.1171. [DOI] [PubMed] [Google Scholar]
- 32.Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience. 2000;97:279–284. doi: 10.1016/S0306-4522(00)00077-4. [DOI] [PubMed] [Google Scholar]
- 33.Bassil F, et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc. Natl Acad. Sci. USA. 2016;113:9593–9598. doi: 10.1073/pnas.1609291113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Daher JP, et al. Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol. Neurodegener. 2009;4:34. doi: 10.1186/1750-1326-4-34. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Bertoncini CW, et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl Acad. Sci. USA. 2005;102:1430–1435. doi: 10.1073/pnas.0407146102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M, Dobson CM. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J. Am. Chem. Soc. 2005;127:476–477. doi: 10.1021/ja044834j. [DOI] [PubMed] [Google Scholar]
- 37.Auluck PK, Caraveo G, Lindquist S. α-Synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu. Rev. Cell Dev. Biol. 2010;26:211–233. doi: 10.1146/annurev.cellbio.042308.113313. [DOI] [PubMed] [Google Scholar]
- 38.Burmann BM, et al. Regulation of α-synuclein by chaperones in mammalian cells. Nature. 2020;577:127–132. doi: 10.1038/s41586-019-1808-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Zhang MY, Beyer CE. Measurement of neurotransmitters from extracellular fluid in brain by in vivo microdialysis and chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 2006;40:492–499. doi: 10.1016/j.jpba.2005.07.025. [DOI] [PubMed] [Google Scholar]
- 40.Watson JB, et al. Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience. 2009;159:501–513. doi: 10.1016/j.neuroscience.2009.01.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Dedmon MM, Christodoulou J, Wilson MR, Dobson CM. Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J. Biol. Chem. 2005;280:14733–14740. doi: 10.1074/jbc.M413024200. [DOI] [PubMed] [Google Scholar]
- 42.Gao X, et al. Human Hsp70 disaggregase reverses parkinson’s-linked α-Synuclein amyloid fibrils. Mol. Cell. 2015;59:781–793. doi: 10.1016/j.molcel.2015.07.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Yagi-Utsumi M, Satoh T, Kato K. Structural basis of redox-dependent substrate binding of protein disulfide isomerase. Sci. Rep. 2015;5:13909. doi: 10.1038/srep13909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Wilkinson B, Gilbert HF. Protein disulfide isomerase. Biochim. Biophys. Acta. 2004;1699:35–44. doi: 10.1016/S1570-9639(04)00063-9. [DOI] [PubMed] [Google Scholar]
- 45.Bhattacharyya D, et al. Multitude NMR studies of α-synuclein familial mutants: probing their differential aggregation propensities. Chem. Commun. (Camb.) 2018;54:3605–3608. doi: 10.1039/C7CC09597J. [DOI] [PubMed] [Google Scholar]
- 46.Lee HJ, Choi C, Lee SJ. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 2002;277:671–678. doi: 10.1074/jbc.M107045200. [DOI] [PubMed] [Google Scholar]
- 47.Robotta M, et al. Alpha-synuclein binds to the inner membrane of mitochondria in an α-helical conformation. Chembiochem. 2014;15:2499–2502. doi: 10.1002/cbic.201402281. [DOI] [PubMed] [Google Scholar]
- 48.Cole NB, Dieuliis D, Leo P, Mitchell DC, Nussbaum RL. Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp. Cell Res. 2008;314:2076–2089. doi: 10.1016/j.yexcr.2008.03.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Nakamura K, et al. Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J. Neurosci. 2008;28:12305–12317. doi: 10.1523/JNEUROSCI.3088-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Zigoneanu IG, Yang YJ, Krois AS, Haque E, Pielak GJ. Interaction of α-synuclein with vesicles that mimic mitochondrial membranes. Biochim. Biophys. Acta. 2012;1818:512–519. doi: 10.1016/j.bbamem.2011.11.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Bodner CR, Dobson CM, Bax A. Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. J. Mol. Biol. 2009;390:775–790. doi: 10.1016/j.jmb.2009.05.066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Ranjan P, Kumar A. The involvement of His50 during protein disulfide isomerase binding is essential for inhibiting α-syn fibril formation. Biochemistry. 2016;55:2677–2680. doi: 10.1021/acs.biochem.6b00280. [DOI] [PubMed] [Google Scholar]
- 53.Yan P, et al. Defining the mechanism of PDI interaction with disulfide-free amyloidogenic proteins: Implications for exogenous protein expression and neurodegenerative disease. Int. J. Biol. Macromol. 2021;174:175–184. doi: 10.1016/j.ijbiomac.2021.01.172. [DOI] [PubMed] [Google Scholar]
- 54.Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008;283:9089–9100. doi: 10.1074/jbc.M710012200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. 2008;65:1272–1284. doi: 10.1007/s00018-008-7589-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Ghio S, et al. Cardiolipin promotes pore-forming activity of alpha-Synuclein oligomers in mitochondrial membranes. ACS Chem. Neurosci. 2019;10:3815–3829. doi: 10.1021/acschemneuro.9b00320. [DOI] [PubMed] [Google Scholar]
- 57.Cai J, Yang J, Jones DP. Mitochondrial control of apoptosis: the role of cytochrome c. Biochim. Biophys. Acta. 1998;1366:139–149. doi: 10.1016/S0005-2728(98)00109-1. [DOI] [PubMed] [Google Scholar]
- 58.Gillies LA, Kuwana T. Apoptosis regulation at the mitochondrial outer membrane. J. Cell. Biochem. 2014;115:632–640. doi: 10.1002/jcb.24709. [DOI] [PubMed] [Google Scholar]
- 59.Khurana R, et al. Mechanism of thioflavin T binding to amyloid fibrils. J. Struct. Biol. 2005;151:229–238. doi: 10.1016/j.jsb.2005.06.006. [DOI] [PubMed] [Google Scholar]
- 60.Ramis R, Ortega-Castro J, Vilanova B, Adrover M. & Frau J. Cu2+, Ca2+, and methionine oxidation expose the hydrophobic α-synuclein NAC domain. Int. J. Biol. Macromol. 2021;169:251–263. doi: 10.1016/j.ijbiomac.2020.12.018. [DOI] [PubMed] [Google Scholar]
- 61.Serrano A, et al. Reversal of alpha-Synuclein fibrillization by protein disulfide isomerase. Front. Cell Dev. Biol. 2020;8:726. doi: 10.3389/fcell.2020.00726. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Cheng H, Wang L, Wang CC. Domain a’ of protein disulfide isomerase plays key role in inhibiting alpha-synuclein fibril formation. Cell Stress Chaperones. 2010;15:415–421. doi: 10.1007/s12192-009-0157-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Doherty CPA, et al. A short motif in the N-terminal region of α-synuclein is critical for both aggregation and function. Nat. Struct. Mol. Biol. 2020;27:249–259. doi: 10.1038/s41594-020-0384-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Alpha-synuclein oligomers: a new hope. Acta Neuropathol. 2017;134:819–838. doi: 10.1007/s00401-017-1755-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Peelaerts W, et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522:340–344. doi: 10.1038/nature14547. [DOI] [PubMed] [Google Scholar]
- 66.Froula JM, et al. Defining α-synuclein species responsible for Parkinson’s disease phenotypes in mice. J. Biol. Chem. 2019;294:10392–10406. doi: 10.1074/jbc.RA119.007743. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Zhou W, et al. Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim. Biophys. Acta. 2010;1802:322–330. doi: 10.1016/j.bbadis.2009.12.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Carija A, et al. Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity. Redox Biol. 2019;22:101135. doi: 10.1016/j.redox.2019.101135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Afitska K, Fucikova A, Shvadchak VV, Yushchenko DA. Modification of C terminus provides new insights into the mechanism of α-Synuclein aggregation. Biophys. J. 2017;113:2182–2191. doi: 10.1016/j.bpj.2017.08.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Binolfi A, et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: A link between structure, binding specificity and fibrillation enhancement. J. Am. Chem. Soc. 2006;128:9893–9901. doi: 10.1021/ja0618649. [DOI] [PubMed] [Google Scholar]
- 71.Hoyer W, Cherny D, Subramaniam V, Jovin TM. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry. 2004;43:16233–16242. doi: 10.1021/bi048453u. [DOI] [PubMed] [Google Scholar]
- 72.Yang, X., Wang, B., Hoop, C. L., Williams, J. K. & Baum, J. NMR unveils an N-terminal interaction interface on acetylated-α-synuclein monomers for recruitment to fibrils. Proc. Natl. Acad. Sci. USA118, e2017452118 (2021). [DOI] [PMC free article] [PubMed]
- 73.Burre J, Sharma M, Sudhof TC. Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J. Neurosci. 2012;32:15227–15242. doi: 10.1523/JNEUROSCI.3545-12.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Zarbiv Y, et al. Lysine residues at the first and second KTKEGV repeats mediate α-Synuclein binding to membrane phospholipids. Neurobiol. Dis. 2014;70:90–98. doi: 10.1016/j.nbd.2014.05.031. [DOI] [PubMed] [Google Scholar]
- 75.Sciacca MF, et al. Lipid-chaperone hypothesis: a common molecular mechanism of membrane disruption by intrinsically disordered proteins. ACS Chem. Neurosci. 2020;11:4336–4350. doi: 10.1021/acschemneuro.0c00588. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Shahmoradian SH, et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 2019;22:1099–1109. doi: 10.1038/s41593-019-0423-2. [DOI] [PubMed] [Google Scholar]
- 77.Nakamura K, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 2011;286:20710–20726. doi: 10.1074/jbc.M110.213538. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Kamp F, et al. Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 2010;29:3571–3589. doi: 10.1038/emboj.2010.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Ryan T, et al. Cardiolipin exposure on the outer mitochondrial membrane modulates α-synuclein. Nat. Commun. 2018;9:817. doi: 10.1038/s41467-018-03241-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007;87:99–163. doi: 10.1152/physrev.00013.2006. [DOI] [PubMed] [Google Scholar]
- 81.Vaux DL. Apoptogenic factors released from mitochondria. Biochim. Biophys. Acta. 2011;1813:546–550. doi: 10.1016/j.bbamcr.2010.08.002. [DOI] [PubMed] [Google Scholar]
- 82.Pfeffer, C. M. & Singh, A. T. K. Apoptosis: a target for anticancer therapy. Int. J. Mol. Sci. 19, 448 (2018). [DOI] [PMC free article] [PubMed]
- 83.Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221–225. doi: 10.1038/nature09663. [DOI] [PubMed] [Google Scholar]
- 84.Gong, Z., Pan, J., Shen, Q., Li, M. & Peng Y. Mitochondrial dysfunction induces NLRP3 inflammasome activation during cerebral ischemia/reperfusion injury. J. Neuroinflammation15, 242 (2018). [DOI] [PMC free article] [PubMed]
- 85.Yu JW, Lee MS. Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance. Arch. Pharm. Res. 2016;39:1503–1518. doi: 10.1007/s12272-016-0827-4. [DOI] [PubMed] [Google Scholar]
- 86.Wang W, et al. Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein α-synuclein. Proc. Natl Acad. Sci. USA. 2016;113:9587–9592. doi: 10.1073/pnas.1610099113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Grunewald A, Kumar KR, Sue CM. New insights into the complex role of mitochondria in Parkinson’s disease. Prog. Neurobiol. 2019;177:73–93. doi: 10.1016/j.pneurobio.2018.09.003. [DOI] [PubMed] [Google Scholar]
- 88.Park JS, Davis RL, Sue CM. Mitochondrial dysfunction in Parkinson’s disease: New mechanistic insights and therapeutic perspectives. Curr. Neurol. Neurosci. Rep. 2018;18:21. doi: 10.1007/s11910-018-0829-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Diepenbroek M, et al. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-synuclein processing, aggregation and synaptic impairment in [A30P]αsyn transgenic mice. Hum. Mol. Genet. 2014;23:3975–3989. doi: 10.1093/hmg/ddu112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Zhang Z, et al. Ca2+ modulating α-synuclein membrane transient interactions revealed by solution NMR spectroscopy. Biochim. Biophys. Acta. 2014;1838:853–858. doi: 10.1016/j.bbamem.2013.11.016. [DOI] [PubMed] [Google Scholar]
- 91.Zhang Z, et al. Calcium accelerates SNARE-mediated lipid mixing through modulating α-synuclein membrane interaction. Biochim. Biophys. Acta, Biomembr. 2018;1860:1848–1853. doi: 10.1016/j.bbamem.2018.03.025. [DOI] [PubMed] [Google Scholar]
- 92.Wang GF, Li C, Pielak GJ. 19F NMR studies of α-synuclein-membrane interactions. Protein Sci. 2010;19:1686–1691. doi: 10.1002/pro.449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Burré J, et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663–1667. doi: 10.1126/science.1195227. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Jiang X, et al. Membrane-mediated disorder-to-order transition of SNAP25 flexible linker facilitates its interaction with syntaxin-1 and SNARE-complex assembly. FASEB J. 2019;33:7985–7994. doi: 10.1096/fj.201802796R. [DOI] [PubMed] [Google Scholar]
- 95.Bai J, Zhang Z, Liu M, Li C. α-Synuclein-lanthanide metal ions interaction: Binding sites, conformation and fibrillation. BMC Biophys. 2015;9:1. doi: 10.1186/s13628-016-0026-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Arai M, Ferreon JC, Wright PE. Quantitative analysis of multisite protein-ligand interactions by NMR: Binding of intrinsically disordered p53 transactivation subdomains with the TAZ2 domain of CBP. J. Am. Chem. Soc. 2012;134:3792–3803. doi: 10.1021/ja209936u. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Iwahara J, Tang C, Marius Clore G. Practical aspects of 1H transverse paramagnetic relaxation enhancement measurements on macromolecules. J. Magn. Reson. 2007;184:185–195. doi: 10.1016/j.jmr.2006.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The full and uncropped gel/blot images are shown in Supplementary Fig. 4. All data generated or analyzed during this study are included in the article and Supplementary Data 1–3.